HoldsUp

Dr. Ford Brewer MD MPH · 2026-04-23 · Ford Brewer (host), Jesus Vega

The Real Reason Statins Are Overprescribed

32 research-tied claims examined: 3 contradicted 3 overstated 4 context 18 supported 4 unverified

18

Supported by research

0:00:01Ford Brewer (host)supportedmoderate

Over 200 million people worldwide take statins on a daily basis.

"Because over 200 million people are taking them on a daily basis." (said at 0:00:01)

Epidemiological reviews and biomedical literature widely estimate that more than 200 million people worldwide are currently prescribed and taking statin therapy on a daily basis for the management of dyslipidemia and prevention of cardiovascular disease.

0:03:56Ford Brewer (host)supportedhigh

Under current US guidelines, 40% or more of older adults qualify for a statin for primary prevention.

"So, under US guidelines, current guidelines, 40% or more of older adults would qualify for a statin for primary prevention." (said at 0:03:56)

Nationally representative analyses of US adults in the National Health and Nutrition Examination Survey (NHANES) demonstrate that under the 2018 AHA/ACC/Multisociety cholesterol guidelines, approximately 46.8% of adults aged 40 to 75 without atherosclerotic cardiovascular disease qualify for primary prevention statin therapy. Among older adults specifically (ages 60 to 75 years without preexisting cardiovascular disease), eligibility under ACC/AHA risk equations exceeds 50% for women and 80% for men.

0:05:38Ford Brewer (host)supportedhigh

In primary prevention, the actual cardiovascular risk reduction provided by statins over 5 years is often in the single digits.

"Primary prevention, the actual risk reduction over 5 years is often in single digits." (said at 0:05:38)

High-certainty evidence from large meta-analyses of randomized clinical trials demonstrates that in primary prevention populations, the absolute risk reduction (ARR) in cardiovascular events and mortality with statin therapy over a typical trial duration (around 3 to 5 years) is modest and consistently in the single digits (typically ranging from under 1% to around 1% to 3%). For example, a comprehensive systematic review and meta-analysis of 21 randomized clinical trials found that statin therapy was associated with absolute risk reductions of 0.8% for all-cause mortality, 1.3% for myocardial infarction, and 0.4% for stroke.

0:06:52Ford Brewer (host)supportedhigh

A major clinical trial reported a 46% relative risk reduction in strokes with statins, which translated to an absolute risk reduction of 1.3% (13 fewer strokes per 1,000 people over 4 years).

"One major trial reported a 46% relative reduction in strokes. And that sounds like a powerful drug, but when you convert that to real-world terms and look at absolute risk, not relative risk, it was 1.3%. ... So, with the 1.3% was really 13 fewer strokes per thousand people over 4 years." (said at 0:06:52)

The speaker's figures correspond directly to the landmark Collaborative Atorvastatin Diabetes Study (CARDS), a multicenter randomized placebo-controlled trial of atorvastatin (10 mg daily) in 2,838 patients with type 2 diabetes. Over a median follow-up of 3.9 years, atorvastatin reduced stroke incidence with a relative risk reduction of 48% (95% CI 11% to 69%), which corresponded to an absolute risk reduction of approximately 1.3% (from 2.8% in the placebo group to 1.5% in the atorvastatin group, or ~13 fewer stroke events per 1,000 treated patients over roughly 4 years).

0:15:25Ford Brewer (host)supportedlow

Statins have generated an estimated $1 trillion in global cumulative sales, and the US statin market alone was valued at $4.5 billion in 2023.

"Statins have generated an estimated $1 trillion dollars in global sales. The US market alone was valued at 4.5 billion even in 2023." (said at 0:15:25)

Published literature reports that global cumulative sales of statins were projected to reach approximately $1 trillion. Industry and market analyses similarly value the contemporary annual US statin market in the range of several billion dollars (~$4.5 billion in 2023), reflecting continued high prescribing volumes despite widespread generic availability.

0:17:03Ford Brewer (host)supportedmoderate

Research in Massachusetts found that physicians who received payments from pharmaceutical companies prescribed measurably more brand-name statins.

"Researchers in Massachusetts found that doctors who received payments from drug companies, that does happen, and they prescribe measurably more brand-name statins" (said at 0:17:03)

A 2016 cross-sectional study linking the Massachusetts physician payment database with 2011 Medicare Part D prescribing claims evaluated 2,444 physicians who prescribed statins. The researchers found that industry payments were significantly associated with increased rates of prescribing brand-name statins (an increase of 0.1% per $1,000 in total payments received, P < .001, and a 4.8% increase associated with payments for educational training, P = .004).

0:23:38Ford Brewer (host)supportedhigh

Coronary artery calcium (CAC) scoring only detects calcified arterial plaque and cannot identify soft (non-calcified) plaque.

"Well, we know people have had nothing but soft plaque on a calcium score. In other words, calcium score only stabilized calcified plaque." (said at 0:23:38)

Coronary artery calcium (CAC) scoring utilizes non-contrast computed tomography specifically to measure and quantify high-density calcified plaque. Studies comparing non-contrast calcium scoring with contrast-enhanced coronary CT angiography (CTCA) show that non-calcified (soft) coronary plaques can be present in individuals with a CAC score of zero. Standard non-contrast CAC scoring has a very low sensitivity (39%) for identifying non-calcified plaque, requiring contrast CT angiography for reliable evaluation.

0:37:29Ford Brewer (host)supportedmoderate

A Danish meta-analysis of statin trials for secondary prevention showed that the average gain in life expectancy across the analyzed group was approximately 4 days.

"He was quoting a Danish meta-analysis. It was a large pooled analysis of several statin trials for secondary prevention, meaning patients who had already had a heart attack. Now, that's how they were defining secondary prevention. They were not defining secondary prevention as they had plaque. They were not very clear about who had metabolic disease. The average gain in life expectancy across that whole group was about 4 days. Days, not years." (said at 0:37:29)

A 2015 Danish systematic review and meta-analysis by Kristensen and colleagues published in BMJ Open analyzed randomized trials of statins to estimate the average postponement of death within trial follow-up periods (ranging from 2.0 to 6.1 years). For secondary prevention trials (5 studies), the median postponement of death across the analyzed cohorts was 4.1 days (ranging from -10 to 27 days).

0:48:50Ford Brewer (host)supportedhigh

The euglycemic hyperinsulinemic clamp is the gold standard for measuring insulin resistance.

"Researchers use the gold standard for measuring insulin resistance: it's called a euglycemic hyperinsulinemic clamp." (said at 0:48:50)

The statement is fully supported. The hyperinsulinemic-euglycemic clamp (also termed the euglycemic-hyperinsulinemic clamp) is universally recognized in biomedical and metabolic research as the gold standard reference technique for directly quantifying insulin sensitivity and insulin resistance in humans. Because the procedure requires continuous intravenous infusions of insulin and glucose with frequent blood sampling to maintain steady euglycemia, surrogate markers (such as HOMA-IR or TyG index) are typically used in routine clinical practice, while the clamp remains the definitive research standard.

0:59:15Ford Brewer (host)supportedhigh

Rosuvastatin is approximately twice as potent as atorvastatin milligram for milligram.

"Rosuvastatin is twice as strong about as atorvastatin. Those are the two more common ones that you see. So, a dose of uh 20 mg, for example, for rosuvastatin is equal to uh a dose of uh 40 of atorvastatin." (said at 0:59:15)

Clinical trial evidence and standard guideline dose equivalencies confirm that rosuvastatin is roughly twice as potent as atorvastatin milligram-for-milligram in lowering low-density lipoprotein cholesterol (LDL-C). In large multicenter randomized comparative trials such as the STELLAR study, rosuvastatin demonstrated superior LDL-C reductions across comparable milligram doses, establishing the standard dose equivalence where 10 mg and 20 mg of rosuvastatin provide LDL-C lowering comparable to 20 mg and 40 mg of atorvastatin, respectively.

1:00:10Jesus Vegasupportedmoderate

Japanese studies have demonstrated that combining very low-dose rosuvastatin (2.5 mg or 5 mg) with ezetimibe leads to arterial plaque regression.

"But you also need to consider that there is rosuvastatin 2.5 or five, and we have seen research where you combine rosuvastatin in very low dose and ezetimibe, and both have an impact on even arterial plaque reversal. Couple of Japanese studies have shown that." (said at 1:00:10)

Japanese clinical trials using intravascular ultrasound (IVUS) have demonstrated that combining low-dose statin therapy (such as rosuvastatin 5 mg/day or low-to-moderate dose atorvastatin) with ezetimibe (10 mg/day) promotes coronary plaque regression. For example, a prospective randomized study in Japanese patients with coronary artery disease evaluated rosuvastatin 5 mg plus ezetimibe 10 mg versus rosuvastatin 5 mg monotherapy, finding a significant reduction in coronary plaque volume (-13.2% vs. -3.1%). Similarly, the Japanese multicenter PRECISE-IVUS trial demonstrated superior coronary atheroma regression when ezetimibe was added to statin therapy.

0:53:10Ford Brewer (host)supportedmoderate

Data from NHANES studies indicates that approximately 50% to nearly 90% of the American population is metabolically compromised or unhealthy.

"So, if you're already metabolically compromised and as we said, that's only about what? 50% of us as shown by the NHANES study a couple of years ago and more like 90% of us, a high-dose statin isn't just a heart drug." (said at 0:53:10)

Nationally representative data from the National Health and Nutrition Examination Survey (NHANES) support the claim. An analysis of NHANES 2009–2016 data by Araújo et al. (2019) evaluated cardiometabolic parameters (waist circumference, fasting glucose/HbA1c, blood pressure, triglycerides, and HDL cholesterol without medication) and found that only 12.2% of US adults met criteria for optimal metabolic health, indicating that approximately 88% were metabolically compromised. A subsequent analysis of NHANES 1999–2018 data by O'Hearn et al. (2022) found that by 2017–2018, optimal cardiometabolic health had declined to just 6.8% of US adults (over 93% suboptimal). Depending on whether less stringent criteria (such as older ATP III definitions or individual risk thresholds) or strict multi-parameter definitions are applied, estimates of metabolically suboptimal or compromised US adults range from roughly 50% to over 90%.

0:57:15Jesus Vegasupportedmoderate

The risk of experiencing a recurrent heart attack is highest during the 6 to 12 months immediately following a myocardial infarction.

"and especially after a heart attack in the 6 months after a heart attack or a year, which is where you have the highest risk to have a a second heart attack" (said at 0:57:15)

Large nationwide registry cohorts and epidemiological studies demonstrate that the risk of recurrent ischemic cardiovascular events (including recurrent myocardial infarction) and cardiovascular death is sharply front-loaded, with the highest hazard rate occurring in the initial 6 to 12 months following an index myocardial infarction. In a nationwide Swedish registry cohort of 97,254 post-MI patients, the risk of a primary composite ischemic endpoint (non-fatal MI, stroke, or CV death) was 18.3% during the first 365 days post-index MI, compared to a cumulative 20.0% across the entire subsequent 3-year follow-up period (PMID: 25586123).

1:02:50Jesus Vegasupportedhigh

Evidence has not been substantial enough to prove that lowering lipoprotein(a) prevents heart attacks.

"Although the evidence hasn't been substantial enough to say you have to lower it to avoid a heart attack, but it gives that peace of mind of having suspenders and a belt" (said at 1:02:50)

The speaker accurately states that current evidence has not yet definitively established that specifically lowering lipoprotein(a) [Lp(a)] prevents heart attacks or major adverse cardiovascular events. While epidemiological and genetic Mendelian randomization studies strongly link elevated Lp(a) to cardiovascular disease risk, dedicated clinical trials evaluating targeted Lp(a)-lowering therapies (such as pelacarsen, olpasiran, lepodisiran, and zerlasiran) designed to confirm whether lowering Lp(a) translates into a reduction in cardiovascular events like myocardial infarctions remain ongoing. Non-specific agents like PCSK9 inhibitors show secondary reductions in Lp(a) associated with risk reduction (e.g., in the ODYSSEY OUTCOMES trial), but direct clinical proof that lowering Lp(a) per se prevents heart attacks awaits the conclusion of dedicated phase 3 cardiovascular outcome trials.

1:13:15Ford Brewer (host)supportedhigh

Nonsteroidal anti-inflammatory drugs (NSAIDs) do not reduce cardiovascular disease risk.

"They found that some anti-inflammatories like um the nonsteroidal anti-inflammatories, you would think, well, maybe that would help. No, they don't. They don't help at all." (said at 1:13:15)

Large meta-analyses of randomized clinical trials confirm that nonsteroidal anti-inflammatory drugs (NSAIDs)—including both selective COX-2 inhibitors and traditional NSAIDs—do not reduce cardiovascular disease risk. Instead, high-dose NSAID regimens (such as diclofenac, ibuprofen, and coxibs) significantly increase the risk of major coronary events, major vascular events, and heart failure, while naproxen does not confer vascular protection.

  • supports: Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta… (Lancet (London, England) 2013) · cited 1799x in the literature
    "Major vascular events were increased by about a third by a coxib (rate ratio [RR] 1·37, 95% CI 1·14-1·66; p=0·0009) or diclofenac (1·41, 1·12-1·78; p=0·0036), chiefly due to an increase in major coronary events (coxibs 1·76, 1·31-2·37; p=0·0001; diclofenac 1·70, 1·19-2·41; p=0·0032). Ibuprofen also significantly increased major coronary events (2·22, 1·10-4·48; p=0·0253), but not major vascular events (1·44, 0·89-2·33). [...] Naproxen did not significantly increase major vascular events (0·93, 0·69-1·27). [...] Heart failure risk was roughly doubled by all NSAIDs." (abstract, results, passage verified)
    pubmedfull study (doi)
1:13:35Ford Brewer (host)supportedmoderate

Inflammatory conditions like rheumatoid arthritis and psoriatic arthritis increase inflammation and heart attack risk as much as full diabetes mellitus does.

"Rheumatoid arthritis, uh psoriatic arthritis, those types of inflammation do significantly They cause as much inflammation and heart attack risk as full diabetes, whereas some other inflammatory diseases don't." (said at 1:13:35)

Large epidemiologic and cohort studies confirm that systemic inflammatory arthritides such as rheumatoid arthritis confer an elevated risk of myocardial infarction comparable to that of diabetes mellitus. A Danish nationwide cohort study of over 4.3 million individuals (Lindhardsen et al., 2011) demonstrated that the adjusted incidence rate ratio (IRR) for myocardial infarction was identical between patients with rheumatoid arthritis (IRR 1.7, 95% CI 1.5–1.9) and patients with diabetes mellitus (IRR 1.7, 95% CI 1.6–1.8; p = 0.64 for difference). Other prospective cohort data have likewise demonstrated comparable cardiovascular event rates between rheumatoid arthritis and diabetes populations.

1:15:15Ford Brewer (host)supportedhigh

Statin-induced new-onset diabetes and muscle side effects are dose-dependent and become significantly more pronounced at high doses.

"The diabetes signal and the muscle problems, they're dose-dependent... These side effects, the diabetes side effects, the muscle problems, those things get much worse at high doses." (said at 1:15:15)

Large-scale individual participant data meta-analyses of double-blind randomized controlled trials confirm that both new-onset diabetes and muscle-related adverse events are dose-dependent and occur at higher rates with intensive/high-dose statin regimens compared to moderate- or low-dose regimens. For diabetes, low-to-moderate intensity statins increase the rate of new-onset diabetes by approximately 10% (RR 1.10, 95% CI 1.04–1.16) compared with placebo, whereas high-intensity statins increase it by 36% (RR 1.36, 95% CI 1.25–1.48). Similarly, for muscle symptoms (pain or weakness), higher-intensity statin regimens confer a larger relative increase across all years (RR 1.08, 95% CI 1.04–1.13) compared with moderate- or low-intensity regimens (RR 1.03, 95% CI 1.00–1.05).

1:20:28Ford Brewer (host)supportedhigh

Red yeast rice contains the active chemical ingredient of early statin pharmaceuticals (monacolin).

"red yeast rice is—you know, it's related to—what's it called? It's got the active ingredients of one of the original statins in it... Monacolin, yeah, that's right. Yeah. Yeah. The active ingredient." (said at 1:20:28)

Red yeast rice contains monacolin K, an active lipid-lowering compound that is chemically identical to lovastatin, the first commercially approved statin pharmaceutical.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.